TETERBORO, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Quest Diagnostics
Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing,
information and services, today announced that it has appointed Mervyn A.
Sahud, M.D., F.A.C.P, as Medical Director for Coagulation.
Dr. Sahud is responsible for leading Quest Diagnostics' national
coagulation laboratory program and enhancing the coagulation testing services
provided to healthcare specialists seeking guidance on test interpretation and
information about Quest Diagnostics' highly complex coagulation studies. In
addition, Dr. Sahud will direct and accelerate current efforts to develop
coagulation tests for dangerous bleeding and blood clotting disorders.
Dr. Sahud is currently an Associate Clinical Professor of Medicine at the
School of Medicine at the University of California San Francisco (UCSF). In
addition, Dr. Sahud is a member of the von Willebrand Disease and Lupus
Anticoagulant Subcommittees of the International Society on Thrombosis and
Haemostastis. Previously, Dr. Sahud served as the Medical Director of the
Coagulation Center in Oakland, California. In addition, Dr. Sahud was until
recently, Chairman of the Red Cross Blood Bank Technical Advisory Committee,
Northern California Section.
"During his more than 30 years of experience as a respected clinical
coagulation thought leader and laboratorian, Dr. Sahud has helped physicians
understand complicated and ever-changing coagulation testing practices and
technology," said Delbert A. Fisher, M.D., Vice President, Science and
Innovation at Quest Diagnostics.
Quest Diagnostics offers a comprehensive and highly competitive menu of
coagulation tests, with more than 150 tests and 20 test panels that enable
clinicians to distinguish among a myriad of blood coagulation disorders,
including hemophilia and antiphospholipid syndrome. In addition, the
coagulation laboratory program provides dedicated coagulation experts
available for clinical guidance across the Quest Diagnostics laboratory
network.
Dr. Sahud serves on the editorial board of Clinical and Applied
Thrombosis/Hemostasis. He is the lead author of numerous peer-reviewed
papers, which have been published in the British Journal of Hematology, Blood
Cells and Molecular Disease.
Dr. Sahud received his medical degree from Finch University of Health
Sciences/The Chicago Medical School, in North Chicago, Illinois, and is
board-certified in internal medicine and hematology. He completed a United
States Public Health Service traineeship in hematology at the University of
California, San Francisco and was the recipient of a Special Fellowship Award
from the National Institutes of Health (NIH).
Quest Diagnostics Incorporated is the nation's leading provider of
diagnostic testing, information and services, providing insights that enable
healthcare professionals to make decisions that improve health. The company
offers the broadest access to diagnostic testing services in the United States
through its national network of laboratories and patient service centers, and
provides interpretive consultation through its extensive medical and
scientific staff. Quest Diagnostics is the leading provider of esoteric
testing, including gene-based medical testing, and also empowers healthcare
organizations and clinicians with state-of-the-art connectivity solutions that
improve patient care. Additional company information is available at:
www.questdiagnostics.com.
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results and
outcomes to be materially different. Certain of these risks and uncertainties
may include, but are not limited to, unanticipated expenditures, changing
relationships with customers, suppliers and strategic partners, conditions of
the economy and other factors described in the Quest Diagnostics Incorporated
2002 Form 10-K and subsequent filings.
SOURCE Quest Diagnostics Incorporated
-0- 10/16/2003
/CONTACT: Jennifer Somers, Manager, External Communications of Quest
Diagnostics Incorporated, +1-201-393-5700,
jennifer.x.somers@questdiagnostics.com/
/Web site: http://www.questdiagnostics.com /
(DGX)